The Celluma, a biophotonic medical device, was approved for six separate indications-for-use, including the treatment of acne, muscle and joint pain, muscle and joint stiffness, muscle spasm, arthritis and compromised local blood circulation.
“Receiving FDA clearance for six separate indications-for-use is a major milestone for us in the development of our product portfolio and the growth of the company,” said Patrick Johnson , president and CEO for BioPhotas in the release. “Our goal in developing the Celluma was to create a safe, effective and convenient device that could be used in the home and in a professional medical setting, and to do that at a fraction of the cost of the competition. We believe we have accomplished that goal with a product that is proprietary in design and novel in clinical application for pain management and certain skin conditions.”
BioPhotas is headquartered in Tustin, Calif.
Related Articles on FDA Clearances:
Riverain Technologies Receives FDA Clearance for ClearRead +Confirm Software
Siesta Medical Receives Additional FDA Clearances for Encore Tongue Suspension System
Vertiflex Receives FDA Clearance of Two Additions to Technology Portfolio
